Articles related to CLINICAL STUDY

Among more than 200 adolescents 12 to 18 years of age over a 68-week period, nearly 75% of those in the treatment group experienced weight loss of > 5%, compared with only about 15% of those with placebo plus lifestyle intervention. GI adverse events were more common in the treatment group.

To combat weight gain after bariatric surgery, a single weekly 1-mg dose of semaglutide outperformed liraglutide at 3-mg daily. About half the semaglutide group were able to lose more than 10% of their body weight, versus about 1/3 for the liraglutide group.

In a retrospectives study with a 13-month follow up, bariatric surgery patients were 16% less likely to die versus matched non-surgical counterparts. However, surgery patients were more than twice as likely to die by suicide and that risk of suicide was significantly higher in those ages 18-34.

Along with well-known prodromal features like tremor, other signs were identified as potential early indicators. These include sensory skin changes, diabetes, inflammatory conditions, sleep apnea, and restless leg syndrome.

With the initial attempt at salvage therapy, the median PFS was 3.5 months. The objective response rate (ORR) for these patients was 43.4%, with strict complete responses (9.2%), very good partial responses (11.8%), and partial responses (22.4%) all being achieved by patients. A significantly longer median OS of 29.9 months compared to 14.6 months for patients who did not achieve an objective response was associated with achieving a partial response or better with the first line of salvage therapy.

In this cohort study of 12,046 patients with cancer and COVID-19, it was discovered that the use of immunotherapy (IO) and other systemic anticancer therapies in combination with baseline immunosuppression was linked to worse outcomes and a higher incidence of cytokine storm in SARS-CoV-2-infected cancer patients.